Commercial

Pro Ad Report: All the data on medical journal spending in 2016

Pro Ad Report: All the data on medical journal spending in 2016

By

The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.

Five things for pharma marketers to know: Friday, March 24, 2017

Five things for pharma marketers to know: Friday, March 24, 2017

By

Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant beefs up Salix salesforce, to relaunch Addyi

By

Valeant added 250 primary care sales reps to promote its Salix portfolio.

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

By

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Allergan to boost investment in DTC for Kybella

Allergan to boost investment in DTC for Kybella

By

Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.

Sales of Keytruda miss analysts' mark

Sales of Keytruda miss analysts' mark

By

Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.

Five things for pharma marketers to know: Monday, January 30, 2017

Five things for pharma marketers to know: Monday, January 30, 2017

By

Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit

Industry hires and promotions: January 2017

Industry hires and promotions: January 2017

By

Endo hires new head of U.S. branded pharma, and three other people moves for you to know about.

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

By

"In Australia, we are the healthcare industry," he says.

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

By

The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.

Five things for pharma marketers to know: Wednesday, December 21, 2016

Five things for pharma marketers to know: Wednesday, December 21, 2016

By

GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores

Five things for pharma marketers to know: Wednesday, December 7, 2016

Five things for pharma marketers to know: Wednesday, December 7, 2016

By

Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

By

Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.

MM&M's top 5 stories in November 2016

MM&M's top 5 stories in November 2016

By

How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

By

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Gilead's Meyers on making deals and finding unmet patient needs

Gilead's Meyers on making deals and finding unmet patient needs

By

The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

By

The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

By

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

By

"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.

Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

By

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

Pharma pushes to share off-label info with payers at FDA hearing

Pharma pushes to share off-label info with payers at FDA hearing

By

Insurers and pharmacy benefit managers already have a sophisticated understanding of clinical data, the industry argued.

The drug industry wins pricing battle in California, likely to fare better with Trump

The drug industry wins pricing battle in California, likely to fare better with Trump

By

But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.

With more marketing spend behind it, Eliquis gains on market leader Xarelto

With more marketing spend behind it, Eliquis gains on market leader Xarelto

By

BMS and Pfizer outspent Johnson & Johnson two-to-one in advertising for their oral anticoagulant last year.

Drugmakers, facing pricing criticism, sell cures in new ads

Drugmakers, facing pricing criticism, sell cures in new ads

By

With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?

Five things for pharma marketers to know: Friday, October 28, 2016

Five things for pharma marketers to know: Friday, October 28, 2016

By

Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle

New science drives biopharma interest in neurological conditions

New science drives biopharma interest in neurological conditions

By

The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.

J&J exec calls California pricing measure 'misguided'

J&J exec calls California pricing measure 'misguided'

By

Voters are set to vote on Proposition 61, which would allow state agencies to pay the same prices for drugs that the VA department pays.

Will Investors Reward Drugmakers That Limit Price Increases?

Will Investors Reward Drugmakers That Limit Price Increases?

By

Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?

Five things for pharma marketers to know: Friday, October 21, 2016

Five things for pharma marketers to know: Friday, October 21, 2016

By

Lawmakers ask for information about price of leukemia drug; Abbott writes down losses from Mylan stake; CVS Health focused on role as health brand

Merck outspends Bristol-Myers Squibb on journal ads for Keytruda

Merck outspends Bristol-Myers Squibb on journal ads for Keytruda

By

Merck doled out more than $2 million to target doctors in the first half of the year, while BMS spent only $863,000.

OPINION

Newsletters